mRNA therapeutics and orally delivered antibodies are next on the docket as I-Mab continues to build out the next generation of its immuno-oncology portfolio. “I-Mab’s innovation comes
I-Mab’s deals with Complix and Shanghai Affinity mark the start of a new discovery initiative to build out the Chinese biotech’s immuno-oncology pipeline. I-Mab Biopharma